MA33989B1 - Formulation d'anticorps et régimes thérapeutiques - Google Patents

Formulation d'anticorps et régimes thérapeutiques

Info

Publication number
MA33989B1
MA33989B1 MA35124A MA35124A MA33989B1 MA 33989 B1 MA33989 B1 MA 33989B1 MA 35124 A MA35124 A MA 35124A MA 35124 A MA35124 A MA 35124A MA 33989 B1 MA33989 B1 MA 33989B1
Authority
MA
Morocco
Prior art keywords
antibody formulation
therapeutic regimes
therapeutic
regimes
antibody
Prior art date
Application number
MA35124A
Other languages
Arabic (ar)
English (en)
Inventor
Dingjiang Liu
Holly Zhuohong Huang
David Andrew Martin
Christopher Boyd Russell
David H Salinger
Scott Walter Baumgartner
Christopher J Endres
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43858045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33989(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Publication of MA33989B1 publication Critical patent/MA33989B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques d'AM-14 et des régimes posologiques thérapeutiques pour le traitement d'une maladie.
MA35124A 2010-01-15 2011-01-12 Formulation d'anticorps et régimes thérapeutiques MA33989B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29538710P 2010-01-15 2010-01-15
US42205910P 2010-12-10 2010-12-10
PCT/US2011/020985 WO2011088120A1 (fr) 2010-01-15 2011-01-12 Formulation d'anticorps et régimes thérapeutiques

Publications (1)

Publication Number Publication Date
MA33989B1 true MA33989B1 (fr) 2013-02-01

Family

ID=43858045

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35124A MA33989B1 (fr) 2010-01-15 2011-01-12 Formulation d'anticorps et régimes thérapeutiques

Country Status (38)

Country Link
US (5) US8883151B2 (fr)
EP (3) EP3632466A1 (fr)
JP (2) JP5743234B2 (fr)
KR (1) KR101766936B1 (fr)
CN (1) CN102821787B (fr)
AR (1) AR079903A1 (fr)
AU (3) AU2011205402B2 (fr)
BR (1) BR112012017150B1 (fr)
CA (1) CA2787128C (fr)
CL (1) CL2012001966A1 (fr)
CO (1) CO6640206A2 (fr)
CR (1) CR20120419A (fr)
CY (2) CY1119852T1 (fr)
DK (2) DK3295957T3 (fr)
EA (2) EA201891433A3 (fr)
ES (2) ES2652637T3 (fr)
HR (1) HRP20171939T1 (fr)
HU (2) HUE035618T2 (fr)
IL (1) IL220602B (fr)
IN (1) IN2012DN06720A (fr)
LT (2) LT3295957T (fr)
MA (1) MA33989B1 (fr)
MX (1) MX349856B (fr)
MY (1) MY182680A (fr)
NO (1) NO2523688T3 (fr)
NZ (1) NZ601125A (fr)
PE (1) PE20121691A1 (fr)
PH (1) PH12012501364A1 (fr)
PL (2) PL3295957T3 (fr)
PT (2) PT3295957T (fr)
RS (2) RS59743B1 (fr)
SG (2) SG182468A1 (fr)
SI (2) SI2523688T1 (fr)
TN (1) TN2012000335A1 (fr)
TW (1) TWI554282B (fr)
UA (1) UA112288C2 (fr)
WO (1) WO2011088120A1 (fr)
ZA (1) ZA201205167B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
SI2523688T1 (en) * 2010-01-15 2018-03-30 Kirin-Amgen, Inc. Formulation of antibodies and therapeutic regimes
DK2531218T3 (en) * 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
US9932403B2 (en) 2010-05-20 2018-04-03 Ablynx Nv Biological materials related to HER3
CA2885176C (fr) 2010-09-22 2018-10-23 Amgen Inc. Immunoglobulines porteuses et leur utilisation
BR112013025866A2 (pt) * 2011-04-07 2016-12-20 Glaxosmithkline Llc formulações com viscosidade reduzida
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140234330A1 (en) * 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013078375A2 (fr) * 2011-11-23 2013-05-30 Amgen Inc. Administration d'un anticorps spécifique hétérodimère anti-alpha-4-bêta-7
CA2866128C (fr) * 2012-03-07 2017-02-28 Eli Lilly And Company Formulation d'anticorps il-17
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
EP3184542A1 (fr) 2012-05-14 2017-06-28 Novo Nordisk A/S Solutions protéiques stabilisées
EP3689369A1 (fr) 2013-03-15 2020-08-05 Amgen, Inc Procédés pour le traitement du psoriasis à l'aide d'un anticorps anti-il-23
US20160031983A1 (en) 2013-03-15 2016-02-04 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
KR102530900B1 (ko) * 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
WO2015175861A1 (fr) 2014-05-16 2015-11-19 Amgen Inc. Dosage pour la détection de populations de cellules th1 et th2
MY186840A (en) * 2014-08-26 2021-08-25 Amgen K A Inc Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
WO2016039319A1 (fr) * 2014-09-10 2016-03-17 日油株式会社 Inhibiteur d'adsorption de protéine et procédé d'inhibition d'adsorption de protéine
CN121371151A (zh) 2014-12-03 2026-01-23 瑞士杰特贝林生物制品有限公司 具有增加的稳定性的包含免疫球蛋白的药物产品
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MX2018003376A (es) 2015-09-17 2018-08-15 Amgen Inc Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.
HK1255922A1 (zh) 2015-11-04 2019-09-06 Astrazeneca Ab 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子
WO2017112536A1 (fr) 2015-12-22 2017-06-29 Amgen Inc. Ccl20 en tant que prédicteur de réponse clinique aux antagonistes d'il23
CN114265251B (zh) 2016-04-19 2024-12-06 Sage电致变色显示有限公司 包括透明导电氧化物层和汇流条的电致变色装置和其形成方法
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
CA2974531A1 (fr) * 2017-07-26 2019-01-26 Michael Giroux Ancrage de securite et event de toit
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
JP2021532176A (ja) 2018-07-13 2021-11-25 アストラゼネカ・コラボレイション・ベンチャーズ・リミテッド・ライアビリティ・カンパニーAstrazeneca Collaboration Ventures, Llc ブラジクマブによる潰瘍性大腸炎の処置
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
WO2021050563A1 (fr) * 2019-09-09 2021-03-18 The Rockefeller University Traitement par anticorps pour le tissu lésionnel de l'hidradénite suppurée
WO2021048359A1 (fr) 2019-09-11 2021-03-18 Bausch Health Ireland Limited Procédés de traitement d'une maladie du foie stéatosique non alcoolique (nafld) à l'aide d'un anticorps il-17 ra
MX2022010120A (es) * 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
CN112891530B (zh) * 2020-06-19 2021-08-24 北京东方百泰生物科技股份有限公司 一种抗il-17ra单克隆抗体的注射制剂
EP4337257A1 (fr) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Composition d'anticorps
EP4537345A1 (fr) * 2022-06-06 2025-04-16 Fusion Pharmaceuticals Inc. Méthodes de dosage d'agents thérapeutiques
WO2024118430A1 (fr) * 2022-12-02 2024-06-06 Regeneron Pharmaceuticals, Inc. Modèle de calcul numérique de mécanique des fluides et procédés d'utilisation

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000835A (en) 1911-06-19 1911-08-15 Stewart A Minnick Calipers.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
AU636608B2 (en) 1989-05-18 1993-05-06 Yeda Research And Development Co. Ltd. Tumor necrosis factor binding protein II, it's purification and antibodies thereto
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
CA2065346C (fr) 1989-09-05 2005-03-29 Craig A. Smith Recepteurs .alpha. et .beta. de facteur de necrose tumorale
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
ES2080098T3 (es) 1989-12-13 1996-02-01 Yeda Res & Dev Expresion de la proteina de union i al factor de necrosis tumoral tbp-i recombinante.
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2243569A (en) 1990-05-02 1991-11-06 Andrew Langdon Brush with timer
EP0464533B1 (fr) 1990-06-28 1998-07-29 Hoechst Aktiengesellschaft Protéines fusionnées avec des portions d'immunoglobulines, leurs production et utilisation
WO1992001002A1 (fr) 1990-07-11 1992-01-23 Teijin Limited Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation
GEP20002142B (en) 1991-01-18 2000-06-25 Amgen Inc Method for Treatment and Prevention of TNF Mediated Diseases
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
EP0611302B1 (fr) 1991-10-15 2000-03-29 MULLARKEY, Michael F. Recepteurs pour le traitement des troubles inflammatoires de phase tardive
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
DE69333027T2 (de) 1992-03-30 2004-05-06 Immunex Corp., Seattle Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
CA2118119C (fr) 1992-04-30 2001-07-31 Robert C. Thompson Methodes de traitement des affections mediees par le facteur de necrose tumorale et l'interleukine-1
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
ES2229264T5 (es) 1995-03-23 2009-12-17 Immunex Corporation Receptor il-17.
US6680057B1 (en) 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
EP0839196B1 (fr) 1995-07-19 2005-05-11 Genetics Institute, LLC Proteines humaines ctla-8 et utilisation de proteines apparentees aux proteines ctla-8
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
AU7408998A (en) 1996-11-27 1998-06-22 Immunex Corporation Method of regulating nitric oxide production
EP1972194A1 (fr) 1996-12-03 2008-09-24 Amgen Fremont Inc. Mammifères transgéniques disposant d'un loci ig comprenant plusieurs régions vh et vk et anticorps produits à partir de ceux-ci
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
EP1015488B1 (fr) 1997-09-17 2009-09-09 Human Genome Sciences, Inc. Proteine de type recepteur d'interleukine 17
ES2292242T5 (es) 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CZ305123B6 (cs) 1999-10-04 2015-05-13 Novartis Vaccines And Diagnostics, Inc. Způsob výroby kapalného farmaceutického prostředku
EP1266002A2 (fr) 2000-03-16 2002-12-18 Amgen Inc., Molecules du type recepteur de l'interleukine 17 et leur utilisation
TWI322154B (en) 2000-03-16 2010-03-21 Amgen Inc Il-17 receptor like molecules and uses thereof
US20030180255A1 (en) 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
CA2425506A1 (fr) 2000-10-18 2002-08-01 Immunex Corporation Methodes de traitement de la polyarthrite rhumatoide a l'aide d'antagonistes de l'il-17
CA2476934C (fr) 2002-02-27 2009-06-16 Immunex Corporation Composition stabilisee du fragment fc et du recepteur tnf comprenant de l'arginine
US20050153880A1 (en) 2002-06-27 2005-07-14 Yukio Goto Methods of treating or preventing ibd with il-18
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
JP2007501252A (ja) 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調整剤を含有する製剤
GB0321703D0 (en) * 2003-09-16 2003-10-15 Imerys Minerals Ltd Surface modified fillers for polymer resin compositions
WO2005063291A1 (fr) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha Preparation medicamenteuse aqueuse stable contenant un anticorps
IL159670A0 (en) 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
JP2008501826A (ja) 2004-06-04 2008-01-24 デジグナー モレキュールズ インコーポレイテッド フリーラジカル硬化可能なポリエステル類およびその使用方法
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
WO2006088925A2 (fr) 2005-02-14 2006-08-24 Wyeth Caracterisation d'interactions de il-17f et de il-17r
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
WO2007019232A2 (fr) 2005-08-03 2007-02-15 Immunogen, Inc. Formulations d'immunoconjugué
CA2618068C (fr) 2005-08-05 2016-02-16 Amgen Inc. Formulations pharmaceutiques de proteine aqueuse stable ou d'anticorps et leur preparation
DE602006009834D1 (de) 2005-09-01 2009-11-26 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
WO2007047738A1 (fr) 2005-10-18 2007-04-26 Zymogenetics, Inc. Antagonistes de il-17c et méthodes d'utilisation desdits antagonistes
US20070135343A1 (en) 2005-11-01 2007-06-14 Wyeth Sodium chloride solution for drug reconstitution or dilution
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
UA99716C2 (ru) * 2006-10-02 2012-09-25 Кирин-Амген Инк. Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra)
CA2666842A1 (fr) 2006-10-18 2008-04-24 Zymogenetics, Inc. Antagonistes de l'il-17c et leurs procedes d'utilisation
FR2910324B1 (fr) 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
EP2129401B8 (fr) * 2006-12-21 2020-01-15 Amgen Inc. Formulations tamponnées stables contenant des polypeptides
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CA2679588A1 (fr) 2007-03-26 2008-10-02 Zymogenetics, Inc. Proteines de fusion solubles il-17ra/rc et procedes afferents
EP2170958A1 (fr) 2007-06-13 2010-04-07 Amgen Inc. Complexe récepteur hétéromère de l'il-17
WO2009006301A2 (fr) 2007-06-29 2009-01-08 Battelle Memorial Institute Stabilisation de protéines
WO2009026122A1 (fr) 2007-08-17 2009-02-26 Amgen Inc. Formulations d'anticorps et de molécules de fusion fc à l'aide de polycations
JP2011514335A (ja) 2008-02-21 2011-05-06 アムジェン インコーポレイテッド Ｉｌ−１７ｒａ−ｉｌ−１７ｒｂアンタゴニストおよび該アンタゴニストの使用
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
SI2523688T1 (en) 2010-01-15 2018-03-30 Kirin-Amgen, Inc. Formulation of antibodies and therapeutic regimes
MX356279B (es) 2010-10-08 2018-05-22 Novartis Ag Star Métodos para el tratamiento de soriasis usando antagonistas de il-17.
EP3214442A1 (fr) 2010-10-25 2017-09-06 F. Hoffmann-La Roche AG Traitement de l'inflammation gastro-intestinale, du psoriasis, de l'asthme, et du psoriasis a
BR112013025845A2 (pt) * 2011-04-07 2018-09-04 Glaxosmithkline Llc formulações com viscosidade reduzida
BR112013025866A2 (pt) * 2011-04-07 2016-12-20 Glaxosmithkline Llc formulações com viscosidade reduzida
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
KR102530900B1 (ko) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
MY186840A (en) 2014-08-26 2021-08-25 Amgen K A Inc Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy

Also Published As

Publication number Publication date
IN2012DN06720A (fr) 2015-10-23
JP2015052017A (ja) 2015-03-19
WO2011088120A9 (fr) 2012-08-09
RS59743B1 (sr) 2020-02-28
DK3295957T3 (da) 2019-10-14
CO6640206A2 (es) 2013-03-22
CA2787128A1 (fr) 2011-07-21
HRP20171939T1 (hr) 2018-03-23
DK2523688T3 (en) 2017-12-04
KR101766936B1 (ko) 2017-08-09
EA031209B1 (ru) 2018-12-28
SG10201604093XA (en) 2016-07-28
US20180346583A1 (en) 2018-12-06
PH12012501364A1 (en) 2012-10-22
WO2011088120A8 (fr) 2012-09-13
EP3632466A1 (fr) 2020-04-08
US20200399384A1 (en) 2020-12-24
PE20121691A1 (es) 2012-12-14
US10808033B2 (en) 2020-10-20
KR20120118036A (ko) 2012-10-25
IL220602B (en) 2019-03-31
HUE046670T2 (hu) 2020-03-30
SG182468A1 (en) 2012-08-30
PT3295957T (pt) 2019-11-12
EP2523688A1 (fr) 2012-11-21
CN102821787A (zh) 2012-12-12
MX349856B (es) 2017-08-16
MX2012008213A (es) 2012-11-06
AU2015202023A1 (en) 2015-05-14
CL2012001966A1 (es) 2013-01-18
CY1119852T1 (el) 2018-06-27
TW201129382A (en) 2011-09-01
TWI554282B (zh) 2016-10-21
US20230192873A1 (en) 2023-06-22
PL3295957T3 (pl) 2020-03-31
AU2011205402A1 (en) 2012-07-12
NZ601125A (en) 2014-08-29
AR079903A1 (es) 2012-02-29
PL2523688T3 (pl) 2018-04-30
SI3295957T1 (sl) 2020-02-28
UA112288C2 (uk) 2016-08-25
EA201290653A1 (ru) 2013-02-28
HUE035618T2 (en) 2018-05-28
CN102821787B (zh) 2015-07-29
US20150017184A1 (en) 2015-01-15
US11505612B2 (en) 2022-11-22
CA2787128C (fr) 2019-06-11
EP2523688B1 (fr) 2017-10-11
JP2013517277A (ja) 2013-05-16
SI2523688T1 (en) 2018-03-30
US20130022621A1 (en) 2013-01-24
AU2015202023B2 (en) 2017-05-18
US10072085B2 (en) 2018-09-11
ZA201205167B (en) 2013-03-27
CY1122466T1 (el) 2020-10-14
NO2523688T3 (fr) 2018-03-10
WO2011088120A1 (fr) 2011-07-21
BR112012017150A2 (pt) 2017-10-10
AU2017216579A1 (en) 2017-09-07
TN2012000335A1 (en) 2013-12-12
EA201891433A3 (ru) 2019-02-28
JP5743234B2 (ja) 2015-07-01
PT2523688T (pt) 2018-01-05
EA031209B9 (ru) 2021-11-19
EA201891433A2 (ru) 2018-11-30
LT3295957T (lt) 2020-01-27
ES2652637T3 (es) 2018-02-05
CR20120419A (es) 2012-11-29
BR112012017150B1 (pt) 2022-03-03
EP3295957A1 (fr) 2018-03-21
EP3295957B1 (fr) 2019-08-07
AU2011205402B2 (en) 2015-02-05
US8883151B2 (en) 2014-11-11
RS56781B1 (sr) 2018-04-30
ES2753216T3 (es) 2020-04-07
MY182680A (en) 2021-01-29
LT2523688T (lt) 2018-03-12

Similar Documents

Publication Publication Date Title
TW201129382A (en) Antibody formulation and therapeutic regimens
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
EA201991484A1 (ru) Лекарственные формы энзалутамида
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
EP2552439A4 (fr) Méthodes d'amélioration de l'administration de médicament et de l'efficacité d'agents thérapeutiques
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
FI20135146A7 (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
EP2848686A4 (fr) Conjugué d'anticorps anti-cdh3 anticorps (p-cadhérine) et médicament
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
MA55033A (fr) Formulation d'anticorps thérapeutique
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
EP2777713A4 (fr) Conjugué médicamenteux de polyéthylèneglycol-oligopeptide d'acides aminés-irinotécan et composition médicamenteuse de celui-ci
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
FR2984750B1 (fr) Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
DE102009018133A8 (de) Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
TR201908151T4 (tr) İzoindolin türevleri.
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
IT1398348B1 (it) Dispositivo per la somministrazione di fluidi in un corpo animale, particolarmente per la somministrazione di agenti terapici tramite infusione endovasale
EP2712321A4 (fr) Vaccin et anticorps pour ureaplasma pour prévenir et traiter une infection d'un être humain, d'un animal et d'une culture cellulaire
EP2667850A4 (fr) Maintien de l'activité de liaison à l'anticorps des conjugués médicamenteux immunosuppressifs